IRCT20200328046886N2招募中3 期
Comparison of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen with Lopinavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19, A randomized, double-blind study
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Getting out the informed consent form from all of the patients or their guardian
- •Aged between 18 to 75
- •Having one of the following symptoms: Dry cough, Severe weakness or fatigue, Dyspnea, Feeling of pain and pressure on the chest, With or without fever greater than 38° C
- •Days from onset of the symptoms equal or less than 7
- •Definitive diagnosis of moderate COVID-19 based on involvement of up to 3 or 4 pulmonary lobes with an area less than one-third the volume of each lobe or involvement of one or two lobes with a larger area on CT scan
- •It is necessary to have all items 1 to 4 and at least one of items 5 and 6
排除标准
- •History of hospitalization because of COVID-19
- •Participate in any other clinical trial for the treatment of COVID-19
- •Patients under mechanical ventilation at the baseline
- •Bradycardia
- •Sensitivity to Atazanavir
- •Active cancer
- •Immune deficiency or immune compromised
- •Baseline abnormal ECG
- •Pregnancy and lactation
- •Renal impairment (CLcr<50 mL/min)
- •Severe hepatic impairment (Child-pough C)
- •Multi organ failure
- •Concomitant use of rifampin, carbamazepine, phenytoin
研究者
相似试验
进行中（未招募）
1 期
Pilotstudy to asses the pharmacokinetics, the efficacy and safety of the combination of atazanavir, dolutegravir and lamivudine in HIV-1 infected patients who experience side-effects, toxicities or resistance to other anti-HIV drugs.HIVMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-004488-19-NLRadboud University Medical Center20
尚未招募
不适用
Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasiabenign prostatic hyperplasiaJPRN-UMIN000002188JR Tokyo General Hospital100
招募中
1 期
A prospective study of efficacy and safety of atezolizumab for patients with non-small cell lung cancer and interstitial pneumoniaJPRN-UMIN000034849ational Health Organization Kyoto Medical Center15
尚未招募
Unknown
A Observational Study to understand the Effectiveness and Tolerability of Azithromycin on Patients with Upper Respiratory Tract Infection.CTRI/2024/04/066497Alembic Pharmaceuticals Ltd.
已完成
3 期
Comparative study of Atibala Avaleha and Darvi Amalaki Avaleha in dysuriaCTRI/2017/06/008901MAM Sumatibhai Shah Ayurved College60